According to the Vogelstein's model of colorectal carcinogenesis, genetic variations in highly penetrant genes may be involved in the colorectal cancer (CRC) pathogenesis. Similarly, aberrant function and/or altered expression of microRNAs (miRNAs) often occur in CRC. In this context, polymorphisms in miRNA-binding sites (miRSNPs) may affect miRNA/target gene interaction, resulting in differential mRNA/protein expression and increased susceptibility to common diseases. To explore this phenomenon, we have mined the 3ʹ untranslated regions (3ʹUTRs) of genes known to be frequently mutated in CRC to search for miRSNPs and tested their association with CRC risk and clinical outcome. Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls). The role of these miRSNPs was also investigated in relation to clinical outcome on a subset of patients with complete follow-up. rs8679 within PARP1 was associated with CRC risk and patients' survival. In the dominant model, carriers of at least one C allele were at a decreased risk of cancer (P = 0.05). The CC genotype in rs8679 was also associated with an increased risk of recurrence/progression in patients that received 5-FU-based chemotherapy (log-rank test P = 0.03). Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04).
Introduction
Colorectal cancer (CRC) ranks among the leading causes of cancerrelated deaths worldwide (1) . In the Czech Republic, the incidence of this kind of cancer ranks the seventh highest worldwide and represents a serious health problem (2 and www.svod.cz). Survival of CRC patients largely depends on the disease stage at diagnosis: the 5-year survival for stage I is 93.6%, whereas it drops dramatically to 8.1% for stage IV patients (3). 5-Fluorouracil (5-FU) is the most frequently used chemotherapeutic agent for treating patients with CRCs. A better understanding of the regulatory factors and signalling pathways that are altered in CRC could provide new insights into disease etiology and individual response to chemotherapeutics.
Decades of studies have revealed that certain genes and pathways, such as KRAS, BRAF, PIK3CA, SMAD7, PARP1, TP53 and mismatch repair genes, are important in initiation and progression of CRC (4) . The KRAS mutational status is a predictive marker for response to established epidermal growth factor receptor (EGFR) inhibitors used for the treatment of advanced CRC. In fact, mutations in KRAS are associated with resistance to anti-EGFR monoclonal antibody (mAb) therapy with cetuximab or panitumumab. The adverse prognostic impact of BRAF mutations has also been documented (5, 6) , while that of PIK3CA mutations on survival has been restricted to patients with a BRAF wild-type tumour (7) .
Genetic variability is an important factor modulating disease onset as well as response to therapy and drug toxicity. For example, inherited changes in DNA repair genes have been indicated as useful tools to identify patients at risk for aberrant pharmacokinetic or pharmacodynamic effects (8) . Genome-wide association studies have identified an increasing number of single nucleotide polymorphisms (SNPs) showing solid associations with CRC risk that have also been replicated in independent cohorts (9, 10) . However, meta-analyses suggest that altogether those SNPs account for only a small proportion of CRC risk so far (11) .
In recent years, the interest on the mechanisms of post-transcriptional regulation of gene expression mediated by microRNAs (miRNAs) has increased. In concomitance, the role of SNPs located within miRNA-binding target sites (miRSNPs) on cancer susceptibility has been highlighted. Thus, subtle effects exerted by SNPs in genes relevant for CRC may contribute to its etiopathogenesis. In this sense, specific genetic variations in regulatory regions such as miRNA target sites may also modulate survival and response to therapy in CRC patients (12) . We recently reported associations between miRSNPs in genes of four relevant DNA repair pathways (nucleotide excision repair, base excision repair (BER), double-strand breaks repair and mismatch repair) and CRC risk or clinical outcome (13) (14) (15) (16) . SNPs in miRNA target regions of important genes for CRC etiology (APC, ATM, BRAF, KRAS, PARP1, PIK3CA, SMAD7 and TP53) may also affect the efficiency of translation of the corresponding proteins. Thus, in the present study, we hypothesised that variations in above genes might modify CRC susceptibility, survival and efficacy of chemotherapy via a modulation of the signalling response and the maintenance of genomic stability.
Materials and Methods

Study population
Blood samples were collected from patients with histologically confirmed CRC, recruited between September 2003 and May 2012 at several oncological departments in the Czech Republic. The study included 1111 CRC patients and 1469 controls that provided biological samples and could be genotyped appropriately. All CRC patients suffered from adenocarcinomas. Cases and controls were previously described in details elsewhere (14) . All subjects were informed and provided written consent to participate in the study and to use their biological samples for genetic analyses, according to the Helsinki declaration. The design of the study was approved by the local Ethics Committees. Lifestyle and demographic characteristics and potential risk factors for CRC, such as body mass index (BMI), diabetes and family/personal history of cancer were collected in structured questionnaires.
Follow-up of the patients
Eight hundred and sixty-six CRC cases were monitored with followup until March 31, 2013 . A second group consisting of 232 CRC patients was recruited later on and followed up until March 31, 2013 . For all subjects, clinical data at the time of diagnosis, including the location of the tumour, the International Union Against Cancer (UICC) tumour-node-metastasis (TNM) stage system, grade and adjuvant or first line FU-based chemotherapy treatment were assembled, along with information about distant metastasis, relapse and date of death. 2 ) infusions both given over 120 min at the same time, followed by 5-FU (400 mg/m 2 ) bolus given over 2-4 min, followed by 5-FU (600 mg/m 2 ) on the first day. On the second day, leucovorin (200 mg/m 2 ) infusion both given over 120 min at the same time, followed by 5-FU (400 mg/m 2 ) bolus given over 2-4 min, followed by 5-FU (600 mg/m 2 ). The recommended dose schedule is given every 2 weeks. Four hundred and forty subjects did not receive any adjuvant chemotherapy after surgery. In this study, the outcome variables measured were 5-FU-based chemotherapy, overall survival (OS) (time from diagnosis until death or censorship), and event-free survival (EFS) (time of surgery or end of chemotherapy until the date of relapse, death or censorship). mCRC patients were not included in the 5-FU-based survival analysis.
Selection of candidate genes and SNPs in miRNAbinding target sites
Eight genes (APC, ATM, BRAF, KRAS, PARP1, PIK3CA, SMAD7 and TP53) frequently mutated in CRC and important for its etiology were included into this analysis. SNPs in miRNA target regions of above genes may also affect the efficiency of translation of the corresponding proteins. Thus, in the present study, we hypothesised that variations in above genes may modify CRC susceptibility, survival and efficacy of chemotherapy via a modulation of the signalling response and the maintenance of genomic stability. All 160 detected SNPs were tested for minor allele frequency (MAF, >5% in Caucasian populations) in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/) to reach an appropriate statistical power. The selection was primarily done by HapMap CEU population. Whenever this was not possible, other populations were checked as well (i.e. 1000 genomes: phase 1, CEU population). SNPs with the required MAF were further tested for the possibility to be in linkage disequilibrium using HaploView (v. 4.2) with the data from HapMap v. 3 (release R2) in the CEU population.
After this selection, 11 SNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) in the 3ʹUTRs of five candidate genes complied with the required selection criteria. The workflow for the selection of the miRSNPs is depicted in Figure 1 .
SNP genotyping
Genomic DNA was isolated from peripheral blood lymphocytes using standard procedures. The DNA samples from cases and controls were randomly placed on plates where an equal number of cases and controls could be run simultaneously. Genotyping of the selected SNPs was carried out by using the KASPar chemistry of LGC Genomics (Hoddesdon, Herts, UK: http://www.lgcgenomics.com/genotyping/ kasp-genotyping-reagents/), as previously described (21) . For quality control purposes, duplicate samples (5% of the total numbers of samples) were repeated for each SNP, and no template controls were included in each plate. The genotype screening was performed simultaneously for cases and controls. The results were regularly confirmed by random re-genotyping of more than 5% of the samples for each polymorphism, which yielded concordant results. The genotypes with unclear results were excluded from the study.
Bioinformatics
For the selected SNPs, the algorithm RNAcofold (http://rna.tbi.univie.ac.at/cgi-bin/RNAcofold.cgi) was run to assess the Gibbs binding free energy (ΔG, expressed in KJ/mol), both for the common and the variant alleles. The algorithm RNAcofold computes the hybridization energy and base-pairing pattern of two RNA sequences (13, 22) . The difference of the free energies between the two alleles was computed as 'variation of ΔG' (i.e. |ΔΔG|). Since the neighbour sequence of each SNP can be a target for different miRNAs, we calculated the sum of the absolute values of ΔΔGs for each SNP (i.e. |ΔΔG|tot = Σ |ΔΔG|) (22) . The |ΔΔG| tot should be considered as a sort of 'disturbance index' predicting the likelihood for a given SNP to affect the function of the 3ʹUTR and it allows a ranking of SNPs for their relevance, as illustrated in previous studies (13, 22) .
We have searched on miRanda (http://www.microrna.org/microrna/getDownloads.do) for the miRSV scores of those miRNAs targeting rs8679 on PARP1 and rs31764370 on KRAS. Similarly, we mined TargetScan (http://www.targetscan.org/vert_71/) for evolutionary conservation of miRNA-binding sites.
Identification of candidate miRSNPs through eQTL analysis
The association between the miSNPs analysed in the study and gene expression levels was obtained from the Genotype-Tissue Expression project (GTEx; https://gtexportal.org/home/, version V6p) and SCAN database (http://www.scandb.org/newinterface/about.html). The GTEx project allows viewing and downloading computed eQTL results and provides a controlled access system for de-identified individual-level genotype, expression and clinical data. The SCAN database provides the number of differentially transcribed genes for each SNP in lymphoblastoid cell lines (LCL) from individuals of Caucasian origin.
Statistical analyses
Chi-square test (1 degree of freedom), with a type-I error threshold set at α = 0.05, was used to verify whether the genotypes were in HardyWeinberg equilibrium in controls. The multivariate logistic regression (MLR) analysis was used to test the association between genotypes and risk of CRC. The covariates analysed in the multivariate model were sex, age, smoking habit (non-smokers vs. smokers and ex-smokers), BMI, any positive familial history of CRC, education level (high, intermediate and low) and living area (country, town neighbourhood and town). The association between SNPs and CRC risk was calculated by estimating the odds ratio (ORs) and their 95% confidence intervals (CI), adjusted for both continuous and discrete covariates. For all the genotypes, regression coefficients for the additive model were estimated. For all SNPs with significant p values per genotype, the best model (dominant or recessive) was calculated. The Bonferronicorrected significance threshold is 0.006 (for 9 SNPs and α = 0.05).
To overcome a potential age effect due to the difference between cases and controls, they were matched by age quartiles through bootstrap sampling (10 repetitions). For each subset, the association between investigated SNPs and CRC risk was recalculated by estimating the ORs and their 95% CI adjusted for both continuous and discrete covariates (including age).
OS in CRC patients was evaluated using the date of death or the date of the end of the study (August 31, 2011) as the end point of follow-up. For the EFS, in patients who did not have distant metastasis at the time of diagnosis, date of relapse, death or end of the study was used as the end point of follow-up. EFS was defined as the time from surgery/end of therapy to the occurrence of distant metastasis, recurrence or death, whichever came first. The relative risk of death and recurrence was estimated as hazard ratio (HR) using Cox regression. The survival curves for overall and EFS were derived by the Kaplan-Meier method. Multivariate survival analyses were adjusted for age, gender, T, N, M and chemotherapy. Statistical analyses were performed using R (http://www.rproject.org, R version 2.14-2).
Results
SNP selection
Out of the eight genes selected (APC, ATM, BRAF, KRAS, PARP1, PIK3CA, SMAD7 and TP53), only five had miRSNPs in their 3ʹUTRs (160 miRSNPs retrieved). All miRSNPs were filtered according to the study criteria previously described (i.e. MAF and linkage disequilibrium (LD)). In total, 149 SNPs were excluded. Finally, 11 SNPs in 5 genes (rs1804197, rs397768 and rs41116 in APC; rs1137918, rs227091 and rs4585 in ATM; rs712, rs1137282 and rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) passed the selection and were analysed in the present study. The workflow strategy used in the study for the selection and the analysis of miRSNPs residing in the 3ʹUTR of genes relevant for CRC is depicted in Figure 1 .
After the genotyping run, the assays for SNPs rs1137282 in KRAS and rs227091 in ATM failed to pass their validation. The data from these assays showed only non-specific amplification and so could not be used to generate any genotyping results. All the other SNPs were genotyped successfully. However, rs1137918 in ATM resulted monomorphic in all cases and controls (only AA genotype). Therefore, these three SNPs were not included in the following analyses. Finally, in the present study, we reported the genotype results of eight miRSNPs (Supplementary Table 1 , available at Mutagenesis online).
Case-control study
The characteristics of the study participants are shown in Supplementary Table 2, available at Mutagenesis online. Among the 1111 CRC cases, 731 patients were diagnosed with a tumour in the colon and 377 with rectal cancer (despite for 3 cases the information about the site of the tumour was missing, they remained in the survival analysis since they had complete survival data). Out of the 1469 controls, 688 were cancer-free colonoscopy inspected controls (control group 1) and 781 were healthy blood donor volunteers (control group 2). Compared with subjects of both control groups, CRC cases were more likely to be older and had a slightly higher BMI and were more likely to have a positive family history of CRC and lower formal education. Control group had a higher number of male individuals and current smokers and non-smokers (Supplementary Table 2 , available at Mutagenesis online).
Thirty-one CRC cases and 28 control samples were eliminated due to genotyping faulty. The distribution of genotypes within the studied genes in the controls was in agreement with Hardy-Weinberg equilibrium ( Table 1) . None of the investigated miRSNPs showed an association with CRC risk in a co-dominant model. rs8679 within PARP1 was associated with CRC risk when a dominant model was applied. In particular, carriers of at least one C allele were at a decreased risk of CRC, with a statistically significant OR of 0.82 (95% CI 0.67-1.00, P = 0.05). When outcomes were analysed stratifying for cancer site, carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased rectal cancer risk (OR = 0.65, 95% CI 0.43-1.00, P = 0.05; Table 1 ). SNPs within APC, ATM and SMAD7 were not associated with CRC risk.
However, by taking into account also multiple comparisons (by considering a 5% Bonferroni-corrected significance threshold), none of the above associations remained significant.
Survival analysis
The average (median) OS and EFS for the studied population were 86.5 (80.5) and 72.6 (62.4) months, respectively. In the preliminary univariate assessment of covariates known to affect prognosis, several parameters, such as gender, age, BMI, smoking habit, T, N, M status and chemotherapy treatment, were associated with OS ( Overall, no association with survival was observed for all the analysed SNPs after adjustment for significant covariates (Supplementary Tables 3 and 4 , available at Mutagenesis online). After stratification of patients according to tumour location, carriers of the GT genotype in KRAS rs712 with a malignancy in colon showed a longer OS (HR = 0.71; 95% CI 0.51-0.98, P = 0.04; Supplementary Table 3, available at Mutagenesis online).
In patients undergoing 5-FU-based chemotherapy, rs8679 in PARP1 gene was associated with EFS (log-rank test P = 0.03; Figure 2 ). In the univariate analysis, the CC genotype in rs8679 was associated with an increased risk of recurrence or progression only in patients that received 5-FU-based chemotherapy. Additionally, we have also observed a longer OS in patients carrying the TT genotype of rs712 in KRAS and not undergoing 5-FU-based chemotherapy (HR = 0.60; 95% CI 0.37-0.97, P = 0.04) (Supplementary Table 5 , available at Mutagenesis online).
Further stratification of patients according to the stage of disease did not show any significant associations with the OS or EFS (data not shown).
Identification of candidate miRSNPs through eQTL analysis
According to GTEx data, no significant eQTLs were found for SNP rs8679 and rs61764370 in any tissues. Significant cis-eQTL effect was observed for rs712 and KRAS in brain, lung, nerve, skin, thyroid and esophagus tissues. Strong eQTL effect was also observed for rs712 and CASC1 in nerve and skin tissues. In the SCAN database, we observed several differentially expressed genes associated to rs8679 genotypes. In particular, CDCA7, ULK2 and C11orf76 genes resulted differentially expressed according to the different rs8679 genotypes. For rs712, only SFI1 gene expression was altered but only in population from Nigeria. No significant eQTLs were found for rs61764370.
Searching on miRanda for the miRSV scores of those miRNAs targeting rs8679 on PARP1 and rs31764370 on KRAS, we could not retrieve information for any of the miRNAs predicted to bind on KRAS. On the other hand, for PARP1, 3 out of the 6 miRNAs had a miRSV score (Supplementary Table 6 , available at Mutagenesis online). In general, only miR-335-5p shows a quite high score, for the other miRNAs the values were close to 0.
Additionally, we searched on TargetScan for the target genes (PARP1 and KRAS) and looked whether the predicted miRNAs reported on Supplementary Table VI were binding or not in an evolutionary conserved site. Again, for KRAS none of the predicted miRNAs was found in TargetScan database while the three miRNAs were binding to PARP1 on a poorly conserved site (7-to 8-mer binding). Ex-smokers included in non-smokers.
Discussion
The ability of miRNAs to locate and bind mRNA is critical for regulating transcripts level and protein expression (23) . The discovery of the role played by miRNAs in biological processes has also provided evidence that genetic variations affecting miRNA function may have a pathogenic role in cancer. SNPs within miRNA-binding sites have been demonstrated highly penetrant for certain phenotypes (24) . On the other hand, miRNA-binding site sequences in the majority of protein-coding genes are highly conserved (25) . In the last years, a number of studies have suggested the importance of inherited variants in miRNA target sites to human disease susceptibility and progression (24, 26, 27) . In this respect, we have searched for miRSNPs within the 3ʹUTRs of eight genes commonly mutated in CRC (APC, ATM, BRAF, KRAS, PARP1, PIK3CA, SMAD7 and TP53) to evaluate whether these genetic variations could potentially alter the binding with specific miRNAs. The identified miRSNPs were tested in association with CRC risk and clinical outcomes. There is an increasing interest to identify mutations/variations in genes important in tumourigenesis such as APC, BRAF and KRAS because they are involved in the Wnt and the Ras-Raf-MEK-MAPK signalling cascades (28) . Interestingly, BRAF, PIK3CA and TP53 did not present any miRSNPs while several other polymorphisms were present at a very low allele frequency in the Caucasian population. The most important result was that carriers of at least one C allele in rs8679 located in the 3ʹUTR of PARP1 were at a decreased risk of CRC. Similarly, patients with homozygous variant genotype TT for rs712 in KRAS gene were found to be associated with a decreased rectal cancer risk.
Teo et al. previously observed that individuals homozygous for the variant allele of rs8679 within PARP1 were at increased risks of both breast and bladder cancers (29) . MiR-145-3p is predicted to bind to the region where this polymorphism lies (as reported in Supplementary Table VII ). The predicted difference of binding energy according to the allele (ΔΔG −5.71 kJ/mol) implies that the less common C allele ΔG being less negative than the more common T allele (29, 30) . This suggests a less efficient binding of miR-145-3p in the presence of the C allele on the 3′UTR of PARP1 mRNA and implicates a potentially decreased post-transcriptional repression of PARP1 by this miRNA. Previous studies have reported a downregulation of miR-145 expression in CRC (31) (32) (33) . In CRC cell lines, an ectopic overexpression of miR-145 inhibited cell proliferation, motility and invasion in vitro; on the other hand, a stable overexpression of miR-145 suppressed tumour growth and pulmonary metastasis in vivo (31) . Another miRNA predicted to bind to rs8679 polymorphism is miR-27b, which is frequently downregulated in several malignancies, including lung, breast, colon and prostate cancer (34, 35) . This evidence suggests that miR-27b may function as a tumour suppressor (36) (37) (38) . However, it is still not clear the mechanisms underlying miR-27b downregulation, as well as its targets in human cancers.
We have also calculated the ΔG for the miRNA target region using RNAcofold software as previously described (39, 40) . We have investigated the flanking regions of rs8679 that correspond to the binding sites with the predicted miRNAs. By calculating the ΔG, we can predict the impact of the change of allele to affect or impair the binding with predicted miRNAs evaluating the effect of the presence of the two alleles on miRNA binding. For rs8679, there were six miRNAs that could bind in the same position in presence of both alleles and for which we calculated ΔΔG (as reported in the Supplementary Table VI) . rs8679 is located within a predicted target region for miR-2116-3p, miR-335-5p and miR-4469. These miRNAs showed the highest energy needed to bind to the 3ʹUTR with the common T allele. miR-3074-5p exhibited the opposite trend: the highest binding energy was necessary when binding to the region in the presence of the rare C allele, whereas for miR-27b-5p and miR-188-3p there was almost no difference in the binding between alleles. Thus, the miRNA-mRNA binding when the C allele is present, it might be globally more favourable and, theoretically, in this case, it may result in a more stringent repression of translation (i.e. decreased target gene expression). Interestingly, findings from our association study show that carriers of at least one C allele were at a decreased risk of CRC. With an observed decreased risk of cancer for the C allele carriers, this finding supports once again our initial hypothesis of different allele specificity on miRNA-binding target sites that may be reflected in miRNA regulation.
We have observed that the CC genotype in rs8679 was also associated with an increased risk of recurrence or progression only in patients that received 5-FU-based chemotherapy. In light of our results, genetic variations within PARP1 gene might lead to a decrease in its activity eventually impacting in the failure of apoptosis and ultimately cancer susceptibility. The effectiveness of apoptotic activity after 5-FU treatment could be then lower. As previously mentioned, miR-335-5p is predicted in silico to bind to C allele of rs8679. Recently, increased expression levels of miR-335 were markedly associated with CRC tumour size and differentiation. An overexpression of miR-335 in CRC cells facilitated cell proliferation in vitro and tumour growth in vivo (41) .
The study of the modulating effect of miRNAs on PARP1 protein levels in CRC tumours is particularly important because of the current interest in the use of PARP1 inhibitors as a single agent or as a chemo or radiosensitizer in cancer treatment (42) . Interestingly, for the same polymorphism, the CC genotype was associated with an increased risk of recurrence or progression only in patients that received 5-FU-based chemotherapy. The close association between PARP1 gene and 5-FU-based chemotherapy was shown in the study of Cheng and colleagues (43) . Authors observed a decrease in PARP1 expression in mice with induced liver cancer treated by galactosylated chitosan/5-FU. PARP1 is an enzyme that performs central roles in the repair of damaged DNA since it initiates BER. The activation of PARP1 following severe DNA damage induced by 5-FU results in depletion of cellular energy. In order to prevent the consumption of NAD+ and adenosine triphosphate, activated caspase-3 cleaves and inactivates PARP1, which results in apoptosis (44) . In light of our results, genetic variations within PARP1 gene might lead to a decrease in its activity.
rs61764370, residing in the lethal-7 (let-7) miRNA complementary binding site (LCS6) and rs712 of KRAS 3ʹUTR are two miRSNPs that were previously associated with CRC risk and patients survival (45) (46) (47) (48) (49) (50) . However, according to a recent meta-analysis KRAS rs61764370 is not suitable for personalised therapeutic strategies for CRC outcome (51) . Our results support the conclusions from this study. No comprehensive meta-analysis has been conducted on the predictive role of rs712 yet. Concerning this specific miRSNP, our results are in disagreement with a recent study where T allele carriers had an increased risk of developing CRC (49) . However, this study comprised a considerably smaller population than the present one (339 CRC patients and 313 age-and sex-matched controls). miR-34 family is predicted to bind to the region where this polymorphism lies (reported in Supplementary Table VII) . miR-34a and miR-34b/c are involved in the suppression of epithelial-to-mesenchymal transition (EMT) by directly inhibiting the expression of the EMT-inducing transcription factor (EMT-TF) SNAIL (52) . A few studies have already described that miR-34 family is abnormally expressed in several types of cancers and regulate several cellular events, including cell cycle, cell migration and apoptosis (53, 54) , and since recently miR-34a is considered as a critical mediator of p53 function (55) . miR-34b/c expression was reported to be consistently downregulated in CRC (56, 57) . A meta-analysis showed that miR-34 family members could become potential diagnostic and prognostic biomarkers in some types of human cancer (58) . In addition to the already discussed meta-analysis (51), studies of Zhang et al. (47) , Graziano et al. (45) and Ruzzo et al. (46) focused on patients whose primary tumours were positive for a KRAS codon 61 mutation and who were treated with cetuximab in combination with irinotecan. While some authors (45, 46) found that carriers of the KRAS (LCS6; rs61764370) variant G allele showed worse OS and progression-free survival (PFS), in the study of Zhang et al. (47) , patients with the same allele had longer OS and PFS. Other studies reported an improvement in the survival of early-stage CRC cases with the LCS6 variant (59) and a reduced risk of mortality in latestage CRC for the same carriers (60) . No effect of the LCS6 variant allele was observed on response rate in mCRC receiving cetuximab (48) . Winder et al. (50) found that TT carriers with mutated KRAS treated with irinotecan/cetuximab in the EPIC trial had significantly better PFS compared with those harbouring the G allele (TG + GG).
These conflicting results refer that the LCS6 variant allele has different predictive values in mCRC patients treated with cetuximab alone or in combination with 5-FU/oxaliplatin than in patients treated with cetuximab in combination with irinotecan. As several of the studies reported significant associations with outcomes in well-conducted, prospective studies, the prognostic value of KRAS (LCS6; rs61764370) genotype should be largely dependent on the combination of therapy used in conjunction with the anti-EGFR treatment. Additional studies are required to determine the effectiveness of KRAS miRSNPs in the prognosis of patients treated with specific anti-EGFR therapy regimens. Future studies should also analyse the effect of let-7 and its genetic modulation in early stage patients and those treated with chemotherapy. There are several miRNAs predicted to bind in the region where rs61764370 polymorphism in KRAS gene lies. However, for many of them, there is no evidence on their functionality or expression levels in colorectal tissues. In fact, few data and no publications are retrievable for miR-6089, miR-4705, miR-3975 and miR-6134. miR-1972 resulted the miRNA with more impact in the binding with the region hosting rs61764370. miR-1972 was identified as serum diagnostic miRNA in lung (61) and bladder cancer (62) .
Only three miRNAs are predicted to bind to the region where rs61764370 lies, independently of the allele present. Interestingly, calculating the ΔΔG for the different alleles, the miRNA-mRNA binding is stronger with the presence of the variant G allele. This results in a stronger negative regulation of the target gene expression. miR-3975 and miR-6134, also binding to this region, did not show any difference in the binding with the target region according to the presence of the different alleles (Supplementary Table VI ).
Supposing that miRNA-binding site might result in the change of target gene expression, a cis-eQTL effect was investigated using the GTEx and SCANDB databases. Significant cis-eQTL effect was observed for rs712 and KRAS gene in brain, lung, nerve, skin, thyroid and esophagus tissues. For rs8679 polymorphism, CDCA7, ULK2 and C11orf76 genes resulted differentially expressed. However, mechanisms behind these interactions have to be further clarified. No significant eQTLs were found for rs61764370.
We are aware of some limitations of the present study. For instance, there was a different distribution in age and gender between cases and controls, as well as other parameters such as BMI. We attempted to control the potential age effect by matching cases and controls by age quartiles through bootstrap sampling; however, the results from the MLR did not change considerably between ten different bootstrap rounds of re-sampling.
The principal and novel finding of the present study is an association between rs8679 in PARP1 and either a decreased risk of CRC or an increased risk of recurrence or progression in patients that received 5-FU-based chemotherapy. Further studies are needed to validate our findings and assess this miRSNP as a predictive biomarker in independent patient cohorts, to functionally characterise this genetic variant and to find the biological mechanisms underlying the associations.
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